## peer-review-simulator report

- draft: skills/peer_review_simulator/tests/fixture_draft.md
- article type: single_case
- review context: pre_submission
- target journal: n/a

### Step 1 — Article type

single_case. Title contains "case report"; one patient; CARE-like structure with Introduction / Case Presentation / Discussion / Conclusion. No surgical / case-series / image-case / diagnostic-challenge indicators. Downstream implication: JBI single-case framework is appropriate.

### Step 2 — Ethics & confidentiality

- Informed consent statement: **not present**. No section "Patient Consent" / "Consent" / "Informed consent" anywhere in the manuscript; grep on the body text returns no consent wording.
- IRB / ethics statement: not present (acceptable for many single-case reports, but journal policy should be confirmed via `submission_guidelines_check`).
- Patient-identifying details: age (80) and broad clinical scenario are below the HIPAA Safe Harbor identifiability threshold; no MRN / dates beyond Day numbering / place names / images. Recommend `deidentify_check` for a full audit, but no immediate re-identification red flag from this pass.
- AI disclosure: not present. No "AI Disclosure" subsection; no statement on whether generative-AI tools were used in writing. Flag for the author.
- AI-in-review policy: target journal not supplied; no judgment.

### Step 3 — Core clinical logic

- patient demographics: 80-year-old man
- main clinical problem: dyspnea and fever during daptomycin therapy
- key history: deep-seated soft tissue infection treated with intravenous daptomycin from Day 0; symptom onset Day 12
- key examination findings: bilateral peripheral consolidation on chest CT (no auscultation, vitals, or oxygenation values stated)
- diagnostic tests: chest CT; bronchoalveolar lavage with 42% eosinophils
- differential diagnosis: **not stated** in either Case Presentation or Discussion
- final diagnosis: acute eosinophilic pneumonia attributed to daptomycin
- treatment / intervention: daptomycin discontinued Day 13; oral prednisolone 0.5 mg/kg/day from Day 13
- follow-up duration and outcome: complete resolution by Day 23 (follow-up duration = 10 days from steroid start)
- claimed lesson: daptomycin causes acute eosinophilic pneumonia; prompt discontinuation and corticosteroids are mandatory

### Step 4 — JBI critical appraisal

| # | Item | Verdict | Note |
|---|---|---|---|
| J1 | Patient demographics clearly described? | Partly | Age and sex stated; comorbidity, smoking, prior atopy not stated. |
| J2 | History clear enough to interpret the case? | Partly | Infection type vague ("deep-seated soft tissue"); concomitant antibiotics, prior pulmonary disease, allergy history not stated. |
| J3 | Current clinical condition clearly described? | Partly | Symptoms named (dyspnea, fever) but no oxygenation, respiratory rate, vital signs, severity grading. |
| J4 | Diagnostic tests and assessment appropriate and clearly interpreted? | Partly | BAL eosinophilia (42%) is appropriate, but interpretation is presented as proof of causation rather than supporting evidence; no exclusion of infection (BAL culture / PCR / fungal smear) reported. |
| J5 | Intervention / treatment clearly described? | Yes | Prednisolone dose, route, and start day all stated. |
| J6 | Post-intervention condition clearly described? | Partly | "Complete resolution by Day 23" stated but no objective measure (repeat CT, oxygenation, eosinophil count). |
| J7 | Adverse or unexpected events described? | Unclear | No mention of steroid-related adverse events or recurrence after taper. |
| J8 | Takeaway lessons supported by the case? | Partly | Lesson is reasonable but the single observation does not support the absolute claims ("daptomycin causes", "mandatory"); see Step 5. |

### Step 5 — Clinical plausibility

- Diagnosis plausibility: plausible. BAL eosinophilia >25% with bilateral peripheral consolidation in the setting of recent daptomycin is a recognized pattern.
- Alternative diagnoses considered? **No.** Infectious pneumonia (including atypicals), eosinophilic infiltrate from another drug given concomitantly, parasitic eosinophilia, idiopathic acute eosinophilic pneumonia, and ANCA-associated vasculitis are not discussed or excluded. Causality cannot be assigned without these.
- Temporal relationships: clearly stated (Day 0 → Day 12 onset → Day 13 discontinuation + steroid).
- Test interpretation: 42% BAL eosinophilia is supportive but not specific. Infection workup on BAL is not reported.
- Treatment choices: prednisolone 0.5 mg/kg/day is on the lower end of reported regimens but defensible.
- Outcome claims vs. follow-up duration: "complete resolution" claimed at Day 23 with only 10 days of follow-up; recurrence after steroid taper is not addressed.
- Causality overstated: **yes.** The Discussion states "daptomycin caused" and "the temporal relationship ... proves the causal role". For a single case without rechallenge and without exclusion of alternatives, the strongest defensible claim is "likely drug-induced eosinophilic pneumonia, with daptomycin as the most plausible offending agent."

### Step 6 — Novelty & educational value

- claimed novelty: not explicitly stated.
- bucket: **confirmatory** — daptomycin-induced eosinophilic pneumonia is a recognized entity with prior published reports.
- take-home: consider drug-induced eosinophilic pneumonia when new bilateral peripheral consolidation appears during daptomycin therapy; BAL eosinophilia supports the diagnosis; withdraw the drug.
- holds without novelty? **Yes.** Educational value remains because the diagnostic pitfall (attributing new pulmonary symptoms to progression of the underlying infection) is broadly applicable to general medicine, infectious diseases, and intensive care.

### Step 7 — Literature & discussion

- Discussion compares to previous literature only superficially ("All previous reports show identical clinical features"). No specific prior reports are cited or summarized.
- Similar-cases accuracy: the sweeping claim "all previous reports show identical clinical features" is an over-generalization without supporting citations. Flag for revision.
- Proposed mechanism: not discussed (no mechanistic speculation either way — acceptable for a brief case report).
- Limitations: **not acknowledged.** No discussion of the lack of rechallenge, the absence of an explicit infection workup on BAL, or the short follow-up.
- Conclusions proportional? **No.** "Mandatory" and "always" wording in the Conclusion is not proportional to a single observation.
- new-citation needs: a literature comparison citing prior published reports of daptomycin-induced eosinophilic pneumonia (timing relative to drug initiation, BAL eosinophil thresholds, steroid regimens). Recommend re-invoking `similar_cases_search` with keywords: `daptomycin`, `eosinophilic pneumonia`, `bronchoalveolar lavage`, `case report`.

### Step 8 — Reviewer comments

#### Major Comments

M1. **Differential diagnosis missing.** The Case Presentation and Discussion do not consider alternative diagnoses (infectious pneumonia including atypicals, idiopathic acute eosinophilic pneumonia, other drug exposures, parasitic eosinophilia, ANCA-associated vasculitis). Please add an explicit differential and state how each was excluded. Without this, the attribution to daptomycin cannot be evaluated. (Discussion, paragraph 1.)

M2. **Causality overstated.** The Discussion states that the temporal relationship "proves the causal role of daptomycin" and the Conclusion uses "mandatory" and "always". For a single case without rechallenge and without exclusion of alternative diagnoses, the strongest defensible wording is "likely drug-induced eosinophilic pneumonia, with daptomycin as the most plausible offending agent." Please soften causality claims throughout the Discussion and Conclusion. (Discussion, sentences beginning "This case demonstrates ..." and "The temporal relationship ..."; Conclusion, sentences beginning "Clinicians should ..." and "Prompt discontinuation ...".)

M3. **Informed consent statement missing.** No Patient Consent section appears in the manuscript. Most journals require a written-informed-consent statement for case reports. Please add a sentence such as "Written informed consent was obtained from the patient for publication of this case report and any accompanying images." Confirm the exact wording with `submission_guidelines_check` against the target journal.

#### Minor Comments

m1. **Limitations paragraph absent.** Please add one paragraph at the end of the Discussion acknowledging: single observation, no rechallenge, follow-up only 10 days after steroid initiation, infection workup on BAL not reported. (Discussion, end.)

m2. **Over-generalization in literature comparison.** "All previous reports show identical clinical features" is sweeping and uncited. Either cite the prior reports being summarized or soften to "Several previous reports describe a similar clinical pattern." Recommend re-running `similar_cases_search` for daptomycin / eosinophilic pneumonia to populate the Discussion. (Discussion, paragraph 1, sentence beginning "All previous reports ...".)

m3. **Objective measures of resolution.** Please state the objective markers used to define "complete resolution" by Day 23 (e.g., repeat chest imaging, oxygenation, peripheral eosinophil count). (Case Presentation, final sentence.)

m4. **Demographics and history detail.** Comorbidity, smoking status, prior atopy, and concomitant medications (especially other antibiotics that may also cause eosinophilic pneumonia) should be reported. (Case Presentation.)

m5. **AI disclosure.** If any generative-AI tool was used in writing or editing, please add a brief AI Disclosure subsection with the tool name, version, and scope. Confirm the exact requirement via `submission_guidelines_check`.

### Recommended next skills

Run `care_check` for the CARE 2013 structural audit (not covered here). Run `similar_cases_search` with keywords `daptomycin`, `eosinophilic pneumonia`, `bronchoalveolar lavage`, `case report` to fill the literature-comparison gap noted in Step 7. Run `submission_guidelines_check` once the target journal is selected to lock down consent and AI-disclosure wording.
